IT'S HERE. January is my favorite issue of Market Scope's Ophthalmic Market Perspectives newsletter! We look back at the Top 10 stories in ophthalmology from the past year. Subscribe here: https://lnkd.in/gKGEEJtr It's always tough to whittle the list down to 10 contenders. With so many approvals, deals, and product launches, 2023 was a busy year for eye care! Bausch + Lomb, ZEISS Medical Technology, Roche, Aurion Biotech, and Astellas Pharma were among the industry players making news in 2023. Do you recall a big story that didn't make our list? Let me know in the comments. 👇 #ophthalmology #industrynews #drugapproval #productlaunch #2023trends

With a deep understanding of the complexities of #drugdevelopment in #alopecia areata, we enable innovators to advance their #clinicaltrials in this space with a constant focus on trial acceleration and quality. Discover our global capabilities and #patientcentric, novel approaches in #patientrecruitment and #diversityplanning, as we aim to improve #clinicalresearch. » https://bit.ly/47C4MdM

Indiana continues to shine as a powerhouse in the life sciences sector. The latest publication from Newsweek Investment Reports highlights groundbreaking advancements in global life sciences, and Indiana stands out with its robust growth and recognition as a federal tech hub. Our state is home to 3,100+ life sciences establishments, including giants like Eli Lilly and Company, and is renowned for its leadership in medical device manufacturing. As we look at the global landscape of life sciences, Indiana's contributions are significant - from personalized medicine to advanced manufacturing, our region is driving #innovation and fostering #collaborations that shape the future of healthcare. Take a closer look at the transformative work happening both globally and here in Indiana, with insights from our very own Jane Dunigan-Smith, as well as Daniel O'Connell of Acumen Pharmaceuticals, Inc., and Andrew Lake Wooten, Ph.D. of Orano Med. #lifesciences #healthcare #pharma #radiopharma #medtech #techhub #indiana #advancedmanufacturing

Combination therapies , reduce treatment burden & more personalized approach : That’s the way I like it for a very long time… « Around 15 years ago, vascular endothelial growth factor-A (VEGF-A) inhibitors revolutionized eye care by offering an effective way to treat certain retinal diseases, but we now understand more about the potential limits of this approach. For instance, not everyone achieves a good outcome with anti-VEGFs. It is plausible that these complex diseases cannot be treated by targeting only one cytokine. Additionally, we’re pushing up against something of an “efficacy ceiling” with anti-VEGF treatments. And that is something the team I work with are really laser-focused on: how can we break this status quo? It’s a significant challenge and one Roche is tackling from multiple angles. As a community, I do believe we are making great strides, and I’m optimistic that the next big breakthrough is on the horizon. Secondly, and perhaps with a more long-term perspective, I think it’s going to be critical to move beyond control of disease and towards more preventative and even regenerative treatment approaches. We all know our population is aging, and with that we expect to see significant increases in retinal diseases. We’re not there yet, but the science and the technology are definitely maturing and so my hope – my belief – is that we will be able to shift from treating vision loss towards reversing, and even curing it, in the not-too-distant future. How can combination therapies improve on the standard of care? Combination therapies are exciting as they have the potential to address the mechanisms that are driving retinal disease from multiple angles at once with several potential benefits. First and foremost, there is the potential for improvements in vision outcomes for patients. It may be the key to surpassing the efficacy ceiling we are currently seeing with anti-VEGF treatments. Additionally, combination therapies have the potential to reduce treatment burden by using lower doses of complementary therapies rather than relying on escalating doses of monotherapy. In the future, combination treatments could also provide a more personalized approach to care in retinal disease. If we can successfully develop a number of combination therapies targeted to different pathways, it would offer flexibility to tailor the treatment approach to individual patients. »

Is Dyne Done? While Dyne's corporate website announces a positive spin on DMD clinical trial results, investors were not convinced by safety nor efficacy measures leading to stock drop. CBO, COO, and CMO now announced resignation, leaving the CEO to manage the executive team catastrophe. Regardless, the company will push forward towards registration, perhaps in hopes of receiving special benevolence from Peter Marks along the way... As I am not a specialist in DMD clinical measures, can anyone comment how does the Dyne outcome compares with Sarepta Exondys-51? https://lnkd.in/ey9RwXZF

Because foundations are the cornerstones where your practice is going to lean on.

👁️ 𝐎𝐩𝐡𝐭𝐡𝐚𝐥𝐦𝐨𝐥𝐨𝐠𝐲 𝐍𝐞𝐰𝐬 👁️ The big news that everyone is talking about this week is that Alcon are set to acquire BELKIN Vision and the 𝐄𝐚𝐠𝐥𝐞 𝐃𝐒𝐋𝐓 laser 🦅👀 The news originally stemmed from notification to the Tel-Aviv Stock Exchange with Alcon later confirming that they have entered into an agreement. No financials have been confirmed but reports are that the deal could be worth up to $325 million with milestone payments 📈💰 Belkin CEO, Daria Lemann-Blumenthal said “Belkin Vision was founded on the premise of enhancing access to care. Created and nurtured by our talented team, the Eagle device, the world's first non-contact, automated direct-SLT system, brings a step-change to first-line glaucoma care. This agreement brings us closer to realizing our vision enabling a rapid expansion to reach more doctors and patients globally.” The Eagle received FDA 510(k) clearance back in December and I've had the pleasure of seeing the device up close with demonstrations thanks to Belkin CCO, Andrew Webb. Every recent conference I have attended has always seen a great buzz around the Belkin booth with many doctors and specialists wanting to see the capabilities of the Eagle. I've heard that this has been the same at all shows in the US and globally too 👨🏻⚕️👩🏻⚕️👁️ Alcon has a long standing presence in the glaucoma space with mixed success. On the pharma side, they have always had a strong market presence which they strengthened with acquisitions of companies such as 𝐀𝐞𝐫𝐢𝐞 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 💉💧 On the device side however, their glaucoma acquisitions have not always been huge successes (𝐎𝐩𝐭𝐨𝐧𝐨𝐥 and the Express shunt, 𝐓𝐫𝐚𝐧𝐬𝐜𝐞𝐧𝐝 and CyPass). More recently, the acquisition of 𝐈𝐯𝐚𝐧𝐭𝐢𝐬 and the Hydrus has been very successful for Alcon in making their way back into the MIGS space where they have been able to grow global market share 🌍 With the innovation behind Belkin's technology, now backed by an industry leader, I'm sure that the only result will be success and ultimately a positive impact on patients worldwide 👍🏻✅ #glaucoma #ophthalmology #acquisition #belkinvision #alcon

The success of your clinical development program hinges on having a team with relevant expertise; a team that understands the nuances of your therapeutic area, and the various approval pathways of every indication. That’s why IQVIA Biotech hand-selects the team that’s right for you. Find out more. https://bit.ly/47F4F0G #ClinicalDevelopment #TherapeuticExpertise

We have interviewed Juho Himberg, CEO of Optomed Plc. In the interview Juho Himberg tells us where the company is today, the focus ahead, a potential FDA clearance and gives three reasons as to why the company is a good investment today. Read the interview https://lnkd.in/dJTQkC2u

🔹 **Boston Scientific Acquires Axonics, Inc.** Boston Scientific Corporation (NYSE: BSX) has officially announced a definitive agreement to acquire Axonics, Inc. (Nasdaq: AXNX). The merger is anticipated to complete in the first half of 2024, pending standard closing conditions. 📍Highlights: - Acquisition Price: $71 per share, totaling an equity value of about $3.7 billion. - Focus Area: Axonics specializes in developing devices for urinary and bowel dysfunction treatment. - Innovative Products: Axonics' portfolio includes the Axonics R20™ and F15™ Systems, integral to sacral neuromodulation (SNM) therapy. - FDA Approval: Axonics recently received FDA approval for its fourth-generation Axonics R20 neurostimulator. Meghan Scanlon, Senior VP and President of Urology at Boston Scientific, expressed excitement about integrating Axonics' technologies, enhancing their offerings to healthcare professionals and patients. #HealthTech #MedicalDevices #MergersAndAcquisitions #BostonScientific #Axonics